CASE Op-Ed, Washington Times: No ‘Magic Pill’ for Lowering Costs
Gerard Scimeca – Chairman, CASE April 5, 2019 – https://bit.ly/2IfnhvI In the ongoing public debate on the best way to effectuate...
CASE Op-Ed, RealClear Health: New Cures Coming From Value-Based Outcome Medicine
February 1, 2019 Matthew Kandrch – President, CASE https://bit.ly/2GgtKFJ There is no question America’s healthcare system is too costly. We spend $3.3...
Medicare for All – A Popular Headline with Real Repercussions
Recently, Democrats have reinvigorated calls for a single payer healthcare system, popularized in Senator Bernie Sanders’ “Medicare for all” plan....
Pharmaceutical Importation: Too Dangerous To Allow
Last week, U.S. Department of Health and Human Services Secretary Alex Azar spoke at The Heritage Foundation about the importance...
.@POTUS’ IRA is driving up Part D premiums for millions of Medicare beneficiaries, yet Dems like @SenSanders continue to help tout this disastrous legislation. The Biden-Harris @WhiteHouse is misleading the public on their policy’s real impact.
Two weeks from election day, the supposedly independent @FCC is proposing price regulation of #broadband by restricting what data plans companies can offer.
By prohibiting usage-based plans, the FCC would end up increasing prices FOR EVERYONE, including low-data users!
CASE Letter Urges FDA & FTC to Scrutinize Deal Between L’Oréal and Galderma -- "Both companies are currently under investigation or facing sizable lawsuits from claims that they have used harmful chemicals in their products."
https://caseforconsumers.org/2024/10/21/case-letter-urges-fda-ftc-to-scrutinize-deal-between-loreal-and-galderma/